JP2022062157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022062157A5 JP2022062157A5 JP2022014608A JP2022014608A JP2022062157A5 JP 2022062157 A5 JP2022062157 A5 JP 2022062157A5 JP 2022014608 A JP2022014608 A JP 2022014608A JP 2022014608 A JP2022014608 A JP 2022014608A JP 2022062157 A5 JP2022062157 A5 JP 2022062157A5
- Authority
- JP
- Japan
- Prior art keywords
- binding polypeptide
- effector
- moiety
- galactose
- sialic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 21
- 239000012636 effector Substances 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 5
- 235000000346 sugar Nutrition 0.000 claims 5
- 150000004676 glycans Chemical class 0.000 claims 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical group [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims 4
- 102000030902 Galactosyltransferase Human genes 0.000 claims 3
- 108060003306 Galactosyltransferase Proteins 0.000 claims 3
- 102000051366 Glycosyltransferases Human genes 0.000 claims 3
- 108700023372 Glycosyltransferases Proteins 0.000 claims 3
- 102000003838 Sialyltransferases Human genes 0.000 claims 3
- 108090000141 Sialyltransferases Proteins 0.000 claims 3
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 claims 3
- 239000007800 oxidant agent Substances 0.000 claims 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 3
- 125000005629 sialic acid group Chemical group 0.000 claims 3
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- TXCIAUNLDRJGJZ-UHFFFAOYSA-N CMP-N-acetyl neuraminic acid Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-UHFFFAOYSA-N 0.000 claims 1
- TXCIAUNLDRJGJZ-BILDWYJOSA-N CMP-N-acetyl-beta-neuraminic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@]1(C(O)=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-BILDWYJOSA-N 0.000 claims 1
- 108010015133 Galactose oxidase Proteins 0.000 claims 1
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 claims 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
Claims (20)
- エフェクター部分にコンジュゲートした結合性ポリペプチドを作製する方法であって、
結合性ポリペプチドの天然の、または改変されたN結合型グリカンを1つまたはそれ以上のグリコシルトランスフェラーゼおよび場合により1つまたはそれ以上のグリコシダーゼにより処理して、コンジュゲーションに適した末端の糖残基を作製すること;および
末端の糖残基をエフェクター部分と反応させることを含む、前記方法。 - 1つまたはそれ以上のグリコシダーゼは、不要の糖をN結合型グリカンから除去するために用いられ、1つまたはそれ以上のグリコシルトランスフェラーゼは、特定の糖残基を、結合性ポリペプチドの天然の、または改変されたN-グリカンに付加するために用いられる、請求項1に記載の方法。
- 1つまたはそれ以上のグリコシルトランスフェラーゼは、ガラクトシルトランスフェラーゼおよび/またはシアリルトランスフェラーゼを含む、請求項1または2に記載の方法。
- ガラクトシルトランスフェラーゼとシアリルトランスフェラーゼの両方を使用する、請求項1に記載の方法。
- 末端の糖残基は、ガラクトースまたはシアル酸部分である、請求項1~4のいずれか1項に記載の方法。
- グリカンは、G1F、G1、G2F、G2、G1S1F、G1S1、G2S1F、G2S1、G2S2F、およびG2S2からなる群から選択されるコンジュゲーションに適したガラクトシル化またはシアリル化された構造に変換される、請求項3~5のいずれか1項に記載の方法。
- エフェクター部分にコンジュゲートした結合性ポリペプチドを作製する方法であって、
結合性ポリペプチドの天然の、または改変されたグリカンをシアリルトランスフェラー
ゼおよび/またはガラクトシルトランスフェラーゼで処理して、末端シアル酸および/またはガラクトース残基を導入することにより修飾グリカンを作成すること、
末端シアル酸および/またはガラクトース残基を酸化剤と反応させて、酸化されたシアル酸および/または酸化されたガラクトース残基を作製すること、および
酸化されたシアル酸および/またはガラクトース残基をエフェクター部分と反応させることを含む、前記方法。 - 酸化剤は、過ヨウ素酸ナトリウムである、請求項7に記載の方法。
- 1mM未満の過ヨウ素酸ナトリウムを用いる、請求項8に記載の方法。
- 酸化剤はガラクトースオキシダーゼである、請求項7に記載の方法。
- 結合性ポリペプチドはFcドメインを含み、エフェクター部分は、EUナンバリングによるFcドメインのアミノ酸297位でグリカンにコンジュゲートしている、請求項7~10のいずれか1項に記載の方法。
- 結合性ポリペプチドはFcドメインを含み、エフェクター部分は、EUナンバリングによるFcドメインのアミノ酸298位でグリカンにコンジュゲートしている、請求項7~10のいずれか1項に記載の方法。
- 結合性ポリペプチドはCH1ドメインを含み、エフェクター部分は、KabatナンバリングによるCH1ドメインのアミノ酸114位でグリカンにコンジュゲートしている、請求項7~10のいずれか1項に記載の方法。
- エフェクター部分はアミノオキシ基を含む、請求項7~13のいずれか1項に記載の方法。
- エフェクター部分はヒドラジン基を含む、請求項7~13のいずれか1項に記載の方法。
- UDP-ガラクトース基質の使用をさらに含む、請求項7~15のいずれか1項に記載の方法。
- CMP-シアル酸基質の使用をさらに含む、請求項7~16のいずれか1項に記載の方法。
- エフェクター部分の、結合性ポリペプチドに対する比率は約4未満である、請求項7~17のいずれか1項に記載の方法。
- エフェクター部分の、結合性ポリペプチドに対する比率は約2である、請求項18に記載の方法。
- 請求項7~19のいずれか1項に記載の方法であって、酸化されたシアル酸および/またはガラクトース残基を、式(I):
NH2-Q-CON-X
式(I)
[式中、
A)Qは、NHまたはOであり、
B)CONは、接続部分であり、
C)Xは、細胞毒、検出剤、および標的化部分からなる群から選択される]
を含む部分と反応させることを含む、前記方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023195664A JP2024020447A (ja) | 2013-03-11 | 2023-11-17 | 糖類工学による部位特異的抗体-薬物コンジュゲーション |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361776724P | 2013-03-11 | 2013-03-11 | |
US201361776715P | 2013-03-11 | 2013-03-11 | |
US201361776710P | 2013-03-11 | 2013-03-11 | |
US61/776,715 | 2013-03-11 | ||
US61/776,724 | 2013-03-11 | ||
US61/776,710 | 2013-03-11 | ||
JP2019165052A JP7021159B2 (ja) | 2013-03-11 | 2019-09-11 | 糖類工学による部位特異的抗体-薬物コンジュゲーション |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019165052A Division JP7021159B2 (ja) | 2013-03-11 | 2019-09-11 | 糖類工学による部位特異的抗体-薬物コンジュゲーション |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023195664A Division JP2024020447A (ja) | 2013-03-11 | 2023-11-17 | 糖類工学による部位特異的抗体-薬物コンジュゲーション |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022062157A JP2022062157A (ja) | 2022-04-19 |
JP2022062157A5 true JP2022062157A5 (ja) | 2022-05-31 |
JP7390414B2 JP7390414B2 (ja) | 2023-12-01 |
Family
ID=50543307
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016501017A Active JP6739330B2 (ja) | 2013-03-11 | 2014-03-10 | 高グリコシル化結合性ポリペプチド |
JP2016501047A Active JP6588422B2 (ja) | 2013-03-11 | 2014-03-10 | 糖類工学による部位特異的抗体−薬物コンジュゲーション |
JP2019040108A Active JP7121675B2 (ja) | 2013-03-11 | 2019-03-06 | 高グリコシル化結合性ポリペプチド |
JP2019165052A Active JP7021159B2 (ja) | 2013-03-11 | 2019-09-11 | 糖類工学による部位特異的抗体-薬物コンジュゲーション |
JP2021068088A Active JP7321206B2 (ja) | 2013-03-11 | 2021-04-14 | 高グリコシル化結合性ポリペプチド |
JP2022014608A Active JP7390414B2 (ja) | 2013-03-11 | 2022-02-02 | 糖類工学による部位特異的抗体-薬物コンジュゲーション |
JP2023075428A Pending JP2023099146A (ja) | 2013-03-11 | 2023-05-01 | 高グリコシル化結合性ポリペプチド |
JP2023195664A Pending JP2024020447A (ja) | 2013-03-11 | 2023-11-17 | 糖類工学による部位特異的抗体-薬物コンジュゲーション |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016501017A Active JP6739330B2 (ja) | 2013-03-11 | 2014-03-10 | 高グリコシル化結合性ポリペプチド |
JP2016501047A Active JP6588422B2 (ja) | 2013-03-11 | 2014-03-10 | 糖類工学による部位特異的抗体−薬物コンジュゲーション |
JP2019040108A Active JP7121675B2 (ja) | 2013-03-11 | 2019-03-06 | 高グリコシル化結合性ポリペプチド |
JP2019165052A Active JP7021159B2 (ja) | 2013-03-11 | 2019-09-11 | 糖類工学による部位特異的抗体-薬物コンジュゲーション |
JP2021068088A Active JP7321206B2 (ja) | 2013-03-11 | 2021-04-14 | 高グリコシル化結合性ポリペプチド |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023075428A Pending JP2023099146A (ja) | 2013-03-11 | 2023-05-01 | 高グリコシル化結合性ポリペプチド |
JP2023195664A Pending JP2024020447A (ja) | 2013-03-11 | 2023-11-17 | 糖類工学による部位特異的抗体-薬物コンジュゲーション |
Country Status (14)
Country | Link |
---|---|
US (8) | US9701753B2 (ja) |
EP (5) | EP4098663A1 (ja) |
JP (8) | JP6739330B2 (ja) |
KR (6) | KR20240023184A (ja) |
CN (4) | CN105189555B (ja) |
AU (4) | AU2014249224B2 (ja) |
BR (2) | BR112015020885A2 (ja) |
CA (2) | CA2902530C (ja) |
HK (2) | HK1213271A1 (ja) |
IL (5) | IL275376B2 (ja) |
MX (3) | MX370356B (ja) |
RU (3) | RU2711935C2 (ja) |
SG (3) | SG11201506086SA (ja) |
WO (2) | WO2014164503A1 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8528728B2 (en) | 2010-05-19 | 2013-09-10 | Johnson & Johnson Vision Care, Inc. | Ophthalmic lens disinfecting storage case |
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
CA2902530C (en) | 2013-03-11 | 2023-05-09 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
PT3129067T (pt) * | 2014-03-19 | 2023-03-22 | Genzyme Corp | Glicomanipulação em sítios específicos de frações de direcionamento |
MX2017004664A (es) * | 2014-10-09 | 2017-06-30 | Genzyme Corp | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. |
AR103488A1 (es) * | 2015-01-23 | 2017-05-10 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 |
AU2015242213A1 (en) | 2015-07-12 | 2018-03-08 | Hangzhou Dac Biotech Co., Ltd | Bridge linkers for conjugation of cell-binding molecules |
JP2019515025A (ja) * | 2016-04-04 | 2019-06-06 | ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー | トポイソメラーゼ毒 |
CN106248971B (zh) * | 2016-08-19 | 2017-10-03 | 合肥瀚科迈博生物技术有限公司 | 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途 |
KR102345175B1 (ko) | 2016-11-14 | 2021-12-31 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
US10583191B2 (en) | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
HUE065241T2 (hu) | 2016-12-19 | 2024-05-28 | Medimmune Ltd | LIF elleni antitestek és alkalmazásaik |
WO2018126092A1 (en) | 2016-12-29 | 2018-07-05 | Development Center For Biotechnology | Processes for preparing glycoprotein-drug conjugates |
WO2018178277A1 (en) | 2017-03-29 | 2018-10-04 | Avicenna Oncology Gmbh | New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof |
JP7340517B2 (ja) * | 2017-08-31 | 2023-09-07 | シングロン エスエー | バクテリオシン及び抗菌ペプチドを作製するための方法及び組成物 |
KR102110182B1 (ko) * | 2017-09-20 | 2020-05-14 | 한양대학교 에리카산학협력단 | 신규한 옥심 유도체 화합물 및 이를 포함한 항체-약물 복합체 |
FR3085952B1 (fr) | 2018-09-17 | 2020-10-30 | Centre Nat Rech Scient | Conjugue anticorps-medicament comprenant des derives de quinoline |
WO2021000067A1 (zh) | 2019-06-29 | 2021-01-07 | 杭州多禧生物科技有限公司 | 一种细胞结合分子-Tubulysin衍生物偶联物及其制备方法 |
FI3865155T3 (fi) * | 2020-02-13 | 2023-01-13 | Menetelmä vasta-aineen kohdespesifiseksi modifioimiseksi | |
KR102341642B1 (ko) | 2021-06-24 | 2021-12-21 | 주식회사 글로브 | 플로어용 영상 표출 시스템 |
WO2023109953A1 (zh) * | 2021-12-17 | 2023-06-22 | 信达生物制药(苏州)有限公司 | 靶向Claudin18.2的抗体-药物偶联物 |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
ATE159982T1 (de) | 1988-09-15 | 1997-11-15 | Univ Columbia | Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung |
JP2650358B2 (ja) | 1988-10-06 | 1997-09-03 | 株式会社ニコン | 半透過部材を有する光学装置 |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
US5792456A (en) * | 1994-08-04 | 1998-08-11 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
DK0706799T3 (da) * | 1994-09-16 | 2002-02-25 | Merck Patent Gmbh | Immunkonjugater II |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
CN1173878A (zh) | 1995-10-16 | 1998-02-18 | 尤尼利弗公司 | 双功能或双价抗体片段类似物 |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
SE9601245D0 (sv) | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
US6254868B1 (en) * | 1996-03-20 | 2001-07-03 | Immunomedics, Inc. | Glycosylated humanized B-cell specific antibodies |
CA2262405A1 (en) | 1996-08-02 | 1998-02-12 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6953675B2 (en) * | 1997-11-06 | 2005-10-11 | Immunomedics, Inc. | Landscaped antibodies and antibody fragments for clinical use |
US6001817A (en) * | 1998-01-12 | 1999-12-14 | Unitech Pharmaceuticals, Inc. | Pharmaceutical composition comprised of cisplatin, and processes for making and using same |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
EP1115740A1 (en) | 1998-09-23 | 2001-07-18 | The Regents of the University of California | Synthetic peptides, conjugation reagents and methods |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
CN1237076C (zh) | 1999-01-15 | 2006-01-18 | 杰南技术公司 | 具有改变的效应功能的多肽变体 |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
CN1110322C (zh) * | 1999-07-21 | 2003-06-04 | 中国医学科学院医药生物技术研究所 | 单克隆抗体Fab'-平阳霉素偶联物及其抗肿瘤作用 |
CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US20050107595A1 (en) | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
US7265084B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) * | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7226903B2 (en) * | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
US7696163B2 (en) * | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
EP2298354B1 (en) * | 2001-10-10 | 2014-03-19 | ratiopharm GmbH | Remodelling and glycoconjugation of interferon-beta |
US7795210B2 (en) * | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
MXPA04003333A (es) * | 2001-10-10 | 2006-02-22 | Neose Technologies Inc | Remodelado y glicoconjugacion de peptidos. |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
AU2003209446B2 (en) | 2002-03-01 | 2008-09-25 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20070207142A1 (en) * | 2002-05-08 | 2007-09-06 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
PT1534335E (pt) | 2002-08-14 | 2012-02-28 | Macrogenics Inc | Anticorpos específicos de fcγriib e processos para a sua utilização |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
ATE480562T1 (de) | 2002-10-15 | 2010-09-15 | Facet Biotech Corp | Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese |
AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US20070026485A1 (en) * | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
SI1641823T1 (sl) | 2003-06-12 | 2011-12-30 | Lilly Co Eli | Fuzijski proteini analogni glp-1 |
EP2502935B1 (en) | 2003-08-22 | 2017-03-29 | Biogen MA Inc. | Improved antibodies having altered effector function and methods for making the same |
RU2392324C2 (ru) | 2003-09-18 | 2010-06-20 | Симфоген А/С | Способ связывания интересующих последовательностей |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
JP5020636B2 (ja) | 2003-11-06 | 2012-09-05 | シアトル ジェネティックス, インコーポレイテッド | リガンドに結合体化可能なモノメチルバリン化合物 |
EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
US7001978B2 (en) | 2003-11-19 | 2006-02-21 | Xerox Corporation | Unsaturated ester substituted polymers with reduced halogen content |
WO2005056759A2 (en) | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
CA2552892C (en) * | 2004-01-08 | 2014-08-05 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
EP1706424B1 (en) | 2004-01-12 | 2009-07-22 | Applied Molecular Evolution, Inc. | Fc region variants |
EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
DE602005019038D1 (de) | 2004-05-04 | 2010-03-11 | Novo Nordisk Healthcare Ag | O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung |
WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
CN101014619B (zh) | 2004-07-15 | 2010-11-03 | 赞科股份有限公司 | 优化的Fc变体 |
CN101065151B (zh) * | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
EP1799700A4 (en) | 2004-09-27 | 2009-02-11 | Centocor Inc | SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
JP4829609B2 (ja) | 2004-12-22 | 2011-12-07 | 独立行政法人科学技術振興機構 | ヒト抗体酵素およびその生産方法 |
US8217154B2 (en) | 2005-02-23 | 2012-07-10 | Lipoxen Technologies Limited | Activated sialic acid derivatives for protein derivatisation and conjugation |
DK2343320T3 (da) | 2005-03-25 | 2018-01-29 | Gitr Inc | Anti-gitr-antistoffer og anvendelser deraf |
CA2602663A1 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc variants with optimized properties |
JP2008537941A (ja) * | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するFc変異体 |
WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
CA2611519A1 (en) | 2005-06-17 | 2006-12-28 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
ES2543685T3 (es) | 2005-06-30 | 2015-08-21 | Janssen Biotech, Inc. | Métodos y composiciones con actividad terapéutica mejorada |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
TW200815467A (en) * | 2006-06-06 | 2008-04-01 | Genentech Inc | Anti-DLL4 antibodies and methods using same |
CA2655903A1 (en) | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
US7833260B2 (en) | 2006-07-20 | 2010-11-16 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
US20080242607A1 (en) * | 2006-07-21 | 2008-10-02 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
FI20060946A0 (fi) | 2006-10-26 | 2006-10-26 | Glykos Finland Oy | Influenssaviruksen nukleiinihappoja ja peptidejä |
JP2010512306A (ja) * | 2006-10-27 | 2010-04-22 | ザ ロックフェラー ユニバーシティー | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
PE20081250A1 (es) | 2006-11-28 | 2008-10-07 | Centelion | FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA |
ES2464815T3 (es) | 2007-01-09 | 2014-06-04 | Biogen Idec Ma Inc. | Anticuerpos SP35 y usos de éstos |
WO2008091954A2 (en) | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
AU2008251608B2 (en) | 2007-05-08 | 2014-03-27 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
WO2009045894A1 (en) * | 2007-09-28 | 2009-04-09 | Centocor, Inc. | Methods and structural conformations of antibody preparations with increased resistance to proteases |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
WO2009089396A2 (en) * | 2008-01-08 | 2009-07-16 | Neose Technologies, Inc. | Glycoconjugation of polypeptides using oligosaccharyltransferases |
SI2247620T1 (sl) | 2008-01-31 | 2016-09-30 | Genentech, Inc. | Protitelesa proti CD79b in imunokonjugati in postopki za uporabo |
EP2444491B1 (en) | 2008-04-21 | 2016-11-16 | Novo Nordisk Healthcare Ag | Hyperglycosylated human coagulation factor IX |
CA2735193A1 (en) | 2008-08-26 | 2010-03-11 | Macrogenics, Inc. | T-cell receptor antibodies and methods of use thereof |
EP2233499A1 (en) | 2009-03-26 | 2010-09-29 | CSL Behring AG | Antibody composition with altered Fab sialylation |
US10087236B2 (en) * | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
ES2541369T3 (es) | 2010-02-16 | 2015-07-17 | Novo Nordisk A/S | Factor VIII recombinante modificado |
NZ602161A (en) | 2010-03-04 | 2014-12-24 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
WO2012020065A1 (en) * | 2010-08-10 | 2012-02-16 | Glycotope Gmbh | Fab-glycosylated antibodies |
AR085302A1 (es) * | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
US20140219986A1 (en) | 2011-03-11 | 2014-08-07 | Amicus Therapeutics ,Inc. | Dosing regimens for the treatment of fabry disease |
TWI588156B (zh) | 2011-03-28 | 2017-06-21 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
US9790268B2 (en) * | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
WO2014043361A1 (en) | 2012-09-12 | 2014-03-20 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
CA2902530C (en) | 2013-03-11 | 2023-05-09 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
PT3129067T (pt) | 2014-03-19 | 2023-03-22 | Genzyme Corp | Glicomanipulação em sítios específicos de frações de direcionamento |
AU2015243512B2 (en) | 2014-04-08 | 2020-06-04 | University Of Georgia Research Foundation Inc. | Site-specific antibody-drug glycoconjugates and methods |
MX2017004664A (es) | 2014-10-09 | 2017-06-30 | Genzyme Corp | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. |
AU2020253455A1 (en) | 2019-04-03 | 2021-11-04 | Genzyme Corporation | Anti-alpha beta TCR binding polypeptides with reduced fragmentation |
-
2014
- 2014-03-10 CA CA2902530A patent/CA2902530C/en active Active
- 2014-03-10 KR KR1020247003596A patent/KR20240023184A/ko active Application Filing
- 2014-03-10 MX MX2015012570A patent/MX370356B/es active IP Right Grant
- 2014-03-10 CN CN201480014449.1A patent/CN105189555B/zh active Active
- 2014-03-10 EP EP22171935.4A patent/EP4098663A1/en active Pending
- 2014-03-10 WO PCT/US2014/022623 patent/WO2014164503A1/en active Application Filing
- 2014-03-10 KR KR1020217037637A patent/KR102494631B1/ko active IP Right Grant
- 2014-03-10 CN CN201480014338.0A patent/CN105228645B/zh active Active
- 2014-03-10 JP JP2016501017A patent/JP6739330B2/ja active Active
- 2014-03-10 JP JP2016501047A patent/JP6588422B2/ja active Active
- 2014-03-10 CN CN201910427632.9A patent/CN110256560A/zh active Pending
- 2014-03-10 EP EP18187892.7A patent/EP3424956A1/en not_active Withdrawn
- 2014-03-10 KR KR1020237003194A patent/KR20230020013A/ko not_active Application Discontinuation
- 2014-03-10 SG SG11201506086SA patent/SG11201506086SA/en unknown
- 2014-03-10 AU AU2014249224A patent/AU2014249224B2/en active Active
- 2014-03-10 EP EP14714881.1A patent/EP2970469B1/en active Active
- 2014-03-10 SG SG11201506088RA patent/SG11201506088RA/en unknown
- 2014-03-10 IL IL275376A patent/IL275376B2/en unknown
- 2014-03-10 WO PCT/US2014/022728 patent/WO2014164534A2/en active Application Filing
- 2014-03-10 KR KR1020227023776A patent/KR20220103204A/ko not_active Application Discontinuation
- 2014-03-10 MX MX2015012527A patent/MX370679B/es active IP Right Grant
- 2014-03-10 CA CA2902525A patent/CA2902525C/en active Active
- 2014-03-10 US US14/203,438 patent/US9701753B2/en active Active
- 2014-03-10 CN CN202010633677.4A patent/CN111875705B/zh active Active
- 2014-03-10 AU AU2014249290A patent/AU2014249290B2/en active Active
- 2014-03-10 RU RU2015142992A patent/RU2711935C2/ru active
- 2014-03-10 SG SG10201809779RA patent/SG10201809779RA/en unknown
- 2014-03-10 KR KR1020157027622A patent/KR102330681B1/ko active IP Right Grant
- 2014-03-10 RU RU2020100459A patent/RU2020100459A/ru unknown
- 2014-03-10 EP EP22151876.4A patent/EP4063389A3/en active Pending
- 2014-03-10 US US14/203,479 patent/US9580511B2/en active Active
- 2014-03-10 EP EP14718808.0A patent/EP2983701A2/en not_active Withdrawn
- 2014-03-10 BR BR112015020885A patent/BR112015020885A2/pt not_active Application Discontinuation
- 2014-03-10 KR KR1020157027621A patent/KR102420934B1/ko active IP Right Grant
- 2014-03-10 RU RU2015143057A patent/RU2708314C2/ru active
- 2014-03-10 BR BR112015020315A patent/BR112015020315A2/pt not_active Application Discontinuation
-
2015
- 2015-09-02 IL IL241085A patent/IL241085B/en active IP Right Grant
- 2015-09-02 IL IL241084A patent/IL241084B/en unknown
- 2015-09-11 MX MX2019014833A patent/MX2019014833A/es unknown
-
2016
- 2016-02-01 HK HK16101117.8A patent/HK1213271A1/zh unknown
- 2016-03-01 HK HK16102347.8A patent/HK1214501A1/zh unknown
-
2017
- 2017-01-27 US US15/417,648 patent/US10214589B2/en active Active
- 2017-06-05 US US15/614,015 patent/US10494439B2/en active Active
-
2018
- 2018-12-21 AU AU2018282451A patent/AU2018282451B2/en active Active
-
2019
- 2019-01-03 US US16/238,932 patent/US11130816B2/en active Active
- 2019-03-06 JP JP2019040108A patent/JP7121675B2/ja active Active
- 2019-09-11 JP JP2019165052A patent/JP7021159B2/ja active Active
- 2019-10-17 US US16/655,500 patent/US11807690B2/en active Active
-
2021
- 2021-04-14 JP JP2021068088A patent/JP7321206B2/ja active Active
- 2021-05-27 AU AU2021203458A patent/AU2021203458A1/en active Pending
- 2021-08-17 US US17/404,412 patent/US20220089763A1/en active Pending
-
2022
- 2022-01-17 IL IL289918A patent/IL289918A/en unknown
- 2022-02-02 JP JP2022014608A patent/JP7390414B2/ja active Active
-
2023
- 2023-05-01 JP JP2023075428A patent/JP2023099146A/ja active Pending
- 2023-07-25 IL IL304738A patent/IL304738A/en unknown
- 2023-09-07 US US18/463,047 patent/US20240182595A1/en active Pending
- 2023-11-17 JP JP2023195664A patent/JP2024020447A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022062157A5 (ja) | ||
JP2020000252A5 (ja) | ||
JP2016512426A5 (ja) | ||
CN105829543B (zh) | 糖基改造的抗体、抗体-缀合物及其制备方法 | |
US7388081B2 (en) | Method for manufacturing glycoproteins having human-type glycosylation | |
RU2020100459A (ru) | Сайт-специфическая конъюгация антитело-лекарственное средство посредством гликоинженерии | |
HK1087327A1 (en) | Modified natriuretic compounds, conjugates, and uses thereof | |
WO2005116655A3 (en) | Natriuretic compounds, conjugates, and uses thereof | |
ES2556338T3 (es) | Remodelación y glicoconjugación de péptidos | |
US9987373B2 (en) | Modified glycoprotein, protein-conjugate and process for the preparation thereof | |
Unverzagt et al. | High-efficiency synthesis of sialyloligosaccharides and sialoglycopeptides | |
JP5948627B2 (ja) | 線維芽細胞成長因子(fgf)のリモデリングと糖質ペグ化 | |
WO2005100584A3 (en) | Production of galactosylated glycoproteins in lower eukaryotes | |
JP2015533490A5 (ja) | ||
HRP20230260T1 (hr) | Glikoinženjering ciljajućih dijelova specifičan za mjesto | |
DK0586849T3 (da) | Aminoacrylater, en fremgangsmåde til deres fremstilling og deres anvendelse | |
JP2005521635A5 (ja) | ||
JP2012143250A5 (ja) | ||
WO2021062227A3 (en) | Compositions and methods for treatment of liquid cancers | |
WO2003016329A3 (en) | Glycoconjugates of sialic acid derivates, methods for their production and use thereof | |
Matsui et al. | The occurrence of mouse-type oligosaccharides in mouse-human chimeric immunoglobulin G | |
CHAEN | Production of trehalose by a novel enzymatic method and its applications | |
TW200502251A (en) | Natriuretic compound conjugates, conjugates, and uses thereof | |
WO2006082647A1 (ja) | 免疫力増強物質 | |
EP2884854A1 (en) | A method for reducing the content of gluten proteins in a cereal fraction |